Do private discussions between drug makers and European regulators somehow influence marketing applications that are subsequently submitted for approval?
Concerned about the possibility, European Ombudsman Emily O’Reilly has opened an inquiry into such talks between the European Medicines Agency and the pharmaceutical industry. While the discussions are established practice, the ombudsman found it difficult to obtain a complete picture of how the agency handles these exchanges, a spokeswoman explained.
About the Author Reprints
